Nearly nine million people in the U.S. have an inflammatory skin condition called plaque psoriasis. We're raising awareness ...

A potential world-first cure for hepatitis B, a breakthrough treatment for a rare, life-threatening childhood disease, and a ...

A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

For patients with psoriasis and Type 2 diabetes, the risk of developing chronic kidney disease (CKD) continued to rise ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

The American Academy of Dermatology/National Psoriasis Foundation (AAD/NPF) guidelines state that "topical medications are the most common agents used to treat patients with mild or moderate ...

A new Delphi consensus led by the National Psoriasis Foundation proposes a standardized definition of on-treatment remission ...

Tumor necrosis factor (TNF) inhibitor therapy was effective in reducing the likelihood that psoriasis would progress to ...

Psoriasis is a chronic autoimmune condition that mainly affects the skin. When you have psoriasis, your immune system sends ...

Key Takeaways Psoriasis makes skin cells grow too fast, forming thick, scaly patchesGenes plus triggers like stress, ...

Early biologic response patterns in plaque psoriasis revealed faster remission with anti-IL-17AF and underscored the need for tailored treatment strategies.